Low-dose dopamine induces early recovery of recombinant interleukin-2--impaired renal function.
Recombinant interleukin-2 (rIL-2) can produce impairment of renal function with hypotension, fluid retention, elevated blood urea nitrogen, oliguria and low fractional sodium excretion; these side-effects are a common cause of reduction or interruption of rIL-2 infusion. The aim of this study was to investigate the control and treatment of renal toxicity induced by rIL-2 therapy. Here we show that dopamine, at a low dose of 2 micrograms/kg/min, completely prevented renal toxicity induced by rIL-2. While continuing rIL-2 therapy, 24-h continuous infusion of low-dose dopamine produced a rapid normalisation of urine output and a significant decrease in serum creatinine levels and body weight (P < 0.01), with an early and complete recovery of the rIL-2--impaired renal function: mean recovery time of renal function in patients treated with dopamine was significantly lower (P < 0.05) than in nontreated patients (4.8 days vs. 10 days, respectively).
Cattedra di Oncologia Medica, II Facoltà di Medicina e Chirurgia, Università Federico II, Naples, Italy.
G
G
Palmieri
A
A
Morabito
R
R
Lauria
V
V
Montesarchio
E
E
Matano
B
B
Memoli
C
C
Libetta
A
A
Rea
C
C
Merola
P
P
Correale
D000328:Adult; D000368:Aged; D001835:Body Weight / Q000187:drug effects; D003404:Creatinine / Q000097:blood; D004298:Dopamine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects*; D007674:Kidney Diseases / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy; D007680:Kidney Neoplasms / Q000097:blood / Q000628:therapy; D008297:Male; D008545:Melanoma / Q000097:blood / Q000628:therapy; D008875:Middle Aged; D009846:Oliguria / Q000188:drug therapy; D011994:Recombinant Proteins / Q000009:adverse effects
D007376:Interleukin-2; D011994:Recombinant Proteins; D003404:Creatinine; D004298:Dopamine